American Heart Journal
Volume 156, Issue 6 , Pages 1170-1176 , December 2008

Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure

  • Tamara B. Horwich, MD, MS

      Affiliations

    • Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles, CA
    • ,
  • Adrian F. Hernandez, MD, MHS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • David Dai, PhD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Clyde W. Yancy, MD

      Affiliations

    • Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX
    • ,
  • Gregg C. Fonarow, MD

      Affiliations

    • Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles, CA
    • Corresponding Author InformationReprint requests: Gregg C. Fonarow, MD, Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center, 10833 LeConte Ave, Room 47-123 CHS, Los Angeles, CA 90095-1679.
    • ,
  • for the Get With the Guidelines Steering Committee and Hospitals

Received 22 May 2008 ,Accepted 5 July 2008.

References 

  1. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121:951–957
  2. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700–1707
  3. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3:249–254
  4. Horwich TB, Hamilton MA, Maclellan WR, et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8:216–224
  5. Afsarmanesh N, Horwich TB, Fonarow GC. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J. 2006;152:1077–1083
  6. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42:1933–1940
  7. Christ M, Klima T, Grimm W, et al. Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. Eur Heart J. 2006;27:691–699
  8. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–2261
  9. Horwich TB, Fonarow GC. Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS. Semin Dial. 2007;20:549–553
  10. Kalantar-Zadeh K, Block G, Horwich T, et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004;43:1439–1444
  11. Smaha LA. The American Heart Association Get With the Guidelines program. Am Heart J. 2004;148:S46–S48
  12. LaBresh KA, Ellrodt AG, Gliklich R, et al. Get With the Guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164:203–209
  13. LaBresh KA, Gliklich R, Liljestrand J, et al. Using “Get With the Guidelines” to improve cardiovascular secondary prevention. Jt Comm J Qual Saf. 2003;29:539–550
  14. Fonarow GC, Adams KF, Abraham WT, et al. for the Adhere Scientific Advisory Committee SGaI Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572–580
  15. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000;102:611–616
  16. Horwich TB, Kalantar-Zadeh K, MacLellan WR, et al. Albumin levels predict survival in patients with systolic heart failure. Am Heart J. 2008;155:883–889
  17. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–1053
  18. Fonarow GC, Srikanthan P, Costanzo MR, et al. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108 927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J. 2007;153:74
  19. Arques S, Roux E, Sbragia P, et al. Usefulness of serum albumin concentration for in-hospital risk stratification in frail, elderly patients with acute heart failure. Insights from a prospective, monocenter study. Int J Cardiol. 2008;125:265–267
  20. Araujo JP, Frioes F, Azevedo A, et al. Cholesterol—a marker of nutritional status in mild to moderate heart failure. Int J Cardiol. 2008;(Electronic Publication 2007 January 20)
  21. Sreedhara R, Avram MM, Blanco M, et al. Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. Am J Kidney Dis. 1996;28:937–942
  22. Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38:789–795
  23. Rauchhaus M, Koloczek V, Volk H, et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol. 2000;76:125–133
  24. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055–2059
  25. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428–1434
  26. Miettinen KH, Lassus J, Harjola V, et al. Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur J Heart Fail. 2008;[in press]
  27. Sato Y, Takatsu Y, Kataoka K, et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol. 1999;22:811–813
  28. May HT, Muhlestein JB, Carlquist JF, et al. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol. 2006;98:653–658
  29. Rauchhaus M, Coats AJS, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000;356:930–933
  30. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838–1842
  31. Sandek A, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1561–1569
  32. Horwich TB, MacLellan WR. Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother. 2007;8:3061–3068
  33. Tavazzi L, Tognoni G, Franzosi MG, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6:635–641

 This study was funded by the American Heart Association (Dallas, TX) with support from an unrestricted educational grant from GlaxoSmithKline (Philadelphia, PA). Dr Horwich is supported by the National Institutes of Health 1K23HL085097 (Bethesda, MD). Dr Hernandez is a recipient of an American Heart Association Pharmaceutical Roundtable grant (0675060N) and a research support from GlaxoSmithKline. Dr Horwich has no funding/support to disclose; Dr Dai is an employee of Duke Clinical Research Institute (Durham, NC); Drs Yancy and Fonarow engage in research and are consultants in GlaxoSmithKline and received honorarium from the same company; Dr Fonarow is the chair of the Get With the Guidelines Steering Committee, and holds the Eliot Corday Chair in Cardiovascular Medicine and Science.

PII: S0002-8703(08)00571-1

doi: 10.1016/j.ahj.2008.07.004

American Heart Journal
Volume 156, Issue 6 , Pages 1170-1176 , December 2008

Article Tools

* Image Usage & Resolution